HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors
View original at finance.yahoo.comHYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood NEW YORK, December 06, 2025--(BUSI…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
More than 800,000 people in the world live with hemophilia A or hemophilia B
80% confidencePfizer continues its ongoing effort spanning more than 40 years to improve hemophilia care
80% confidenceHYMPAVZI demonstrates potential as a safe and efficacious treatment option that significantly reduced bleeding episodes and improved certain aspects of health-related quality of life
80% confidenceApproximately 20% of people with hemophilia A and 3% of people with hemophilia B develop inhibitors to factor replacement therapies
80% confidenceThe data demonstrate the potential of HYMPAVZI to combine efficacy, safety, and straightforward administration for adults and adolescents living with hemophilia A or B with inhibitors
80% confidenceHYMPAVZI reduced bleeds by 93% compared to on-demand treatment with bypassing agents in adults and adolescents with hemophilia A or B with inhibitors
80% confidenceThe emergence of inhibitors poses significant treatment challenges and can increase disease burden for people living with hemophilia A or B
80% confidence